Intarcia Therapeutics Inc.
www.intarcia.com
Latest From Intarcia Therapeutics Inc.
Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions
The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.
Deal Watch: Oncternal Goes Public Via Reverse Merger With GTx
All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.
Numab's Pipeline To Benefit From Intarcia Licensing Its ND016
Privately held Swiss immunology and immuno-oncology specialist Numab Therapeutics has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics, and will use the proceeds to advance its own drug pipeline, its co-founder tells Scrip.
Company Information
- Industry
-
Biotechnology
- Large Molecule
-
Medical Devices
- Implantable Devices
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Specialty Pharmaceuticals
-
Drug Delivery
- Therapeutic Areas
- Metabolic Disorders
- Alias(es)
- BioMedicines Inc.
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Intarcia Therapeutics Inc.
- Senior Management
-
Kurt Graves, Chmn., Pres. & CEO
James Ahlers, CFO
Fred Fiedorek, MD, CMO, Global Head, Reg. Affairs
Andrew Young, MD, PhD, CSO - Contact Info
-
Intarcia Therapeutics Inc.
Phone: (617) 936-2500
One Marina Park Dr., 13th Fl.
Boston, MA 02210
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice